On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid ...

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Dr Benjamin George champions innovative oncology care in rural Nebraska, emphasizing collaboration and multidisciplinary ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...